2024-09-06 17:16:02
A box of the drug Mounjaro at a pharmacy in Utah, U.S., March 29, 2023. GEORGE FREY/REUTERS
The High Authority for Health (HAS) has issued favorable opinions subject to conditions for the reimbursement by Health Insurance of the drug Mounjaro from the American pharmaceutical group Eli Lilly, prescribed in the treatment of obesity a you type 2 diabetes. The opinions in these two prescriptionsvalidated in mid-July by the commission that evaluates drugs, were made public on Friday September 6 on X.
In the treatment of obesity, reimbursement of Mounjaro is recommended “only as a complement to a low-calorie diet and increased physical activity in weight control”.
It is recommended that this treatment “should only be prescribed after consultation with a specialist in the management of obesity” in adults with an initial body mass index (BMI) greater than or equal to 35 kg/m² in the event of failure of well-conducted nutritional management (less than 5% weight loss at six months). The commission also considers “it is necessary to assess the effectiveness of the treatment after six months, and to consider possible discontinuation, particularly in the event of weight loss of less than 5%”.
Read the analysis | Article reserved for our subscribers New anti-obesity drugs, public and financial success despite the caution of health professionals
Add to your selections
In the absence of robust comparative data compared to other GLP-1 analogues prescribed in the treatment of obesity, Wegovy (semaglutide) or Saxenda (liraglutide), Mounjaro cannot be prioritised over these molecules, judges the HAS.
In type 2 diabetes, Mounjaro management has been recommended only “in adults for the treatment of inadequately controlled type 2 diabetes as an adjunct to diet and physical activity”et “in 2nd line or 3rd line of treatment”.
Mounjaro belongs to a class of drugs that mimic a gut hormone (GLP-1, short for glugaco-like peptide 1), which stimulates insulin secretion and provides a feeling of satiety.
These new-generation drugs, which also include Wegovy and Ozempic from the Danish Novo Nordisk, are bringing hope to millions of people because they can lead to greater weight loss than previous treatments. They are all the rage on social media and are generating astronomical profits for the pharmaceutical companies that market them.
Read the analysis | Article reserved for our subscribers Anti-obesity drugs: behind Novo Nordisk and Lilly, the competition is accelerating
Add to your selections
Reuse this content
1725690909
#High #Authority #Health #authorizes #reimbursement #conditions #Mounjaro
Tirzepatide weight loss
Table of Contents
Breakthrough in Weight Management: FDA Approves Tirzepatide (Zepbound) for Chronic Weight Loss
The fight against obesity has taken a significant leap forward with the recent FDA approval of Zepbound (tirzepatide) injection for chronic weight management in adults with obesity [[1]]. This milestone marks a new era in weight loss therapy, offering hope to millions of individuals struggling with weight-related health issues.
What is Tirzepatide (Zepbound)?
Tirzepatide, also known as Mounjaro, is a GLP-1 analogue that mimics a gut hormone, stimulating insulin secretion and providing a feeling of satiety. This medication belongs to a class of drugs that has shown remarkable efficacy in weight loss and glucose control.
Weight Loss Results
Studies have demonstrated that tirzepatide can lead to significant weight loss in individuals with obesity. In a recent study, participants with weight/obesity issues who took 10 mg of tirzepatide lost 21% of their body weight after 72 weeks [[2]]. This is a substantial improvement compared to other weight loss treatments, making tirzepatide a promising option for those struggling with weight management.
Comparison to Other GLP-1 Analogues
Research has shown that tirzepatide may have an edge over other GLP-1 analogues, such as semaglutide (Wegovy), in terms of weight loss outcomes. A study published in JAMA Internal Medicine found that tirzepatide resulted in greater weight loss benefits compared to semaglutide [[3]].
Reimbursement and Prescribing Guidelines
The High Authority for Health (HAS) has issued favorable opinions for the reimbursement of Mounjaro (tirzepatide) by Health Insurance for the treatment of obesity and type 2 diabetes. The HAS recommends that Mounjaro be prescribed as a complement to a low-calorie diet and increased physical activity in weight control, and only after consultation with a specialist in the management of obesity.
Conclusion
The FDA approval of Zepbound (tirzepatide) marks a significant breakthrough in the treatment of obesity. With its impressive weight loss results and potential advantages over other GLP-1 analogues, tirzepatide is poised to become a game-changer in the fight against obesity. As the medical community continues to explore the benefits and applications of this medication, individuals struggling with weight-related health issues may finally have access to a safe and effective treatment option.
References:
Keyword optimization for SEO: Tirzepatide, Zepbound, Mounjaro, GLP-1 analogue, weight management, obesity, type 2 diabetes, weight loss treatment.
Mounjaro buy online
Mounjaro for Weight Loss: Safety, Side Effects, and More
Mounjaro, a new-generation drug, has been making waves in the medical community for its potential in treating obesity and type 2 diabetes. The High Authority for Health (HAS) has recently issued favorable opinions for the reimbursement of Mounjaro by Health Insurance, but with certain conditions. In this article, we’ll delve into the safety, side effects, and efficacy of Mounjaro for weight loss.
Efficacy of Mounjaro for Weight Loss
Studies have shown that Mounjaro is highly effective in reducing weight in individuals with obesity. In fact, over 85% of people taking Mounjaro were able to reduce their weight by at least 5%, compared to 35% of people given a placebo [[2]]. Additionally, a new real-world study found that people taking Mounjaro lost more weight faster compared to people who took Ozempic [[3]].
Safety of Mounjaro for Weight Loss
Mounjaro is generally safe for weight loss in individuals who are overweight or living with obesity [[1]]. However, it’s recommended that this treatment should only be prescribed after consultation with a specialist in the management of obesity, and only as a complement to a low-calorie diet and increased physical activity in weight control.
Side Effects of Mounjaro
While Mounjaro is considered safe, it’s not without side effects. Common side effects include nausea, vomiting, diarrhea, and abdominal pain. In rare cases, Mounjaro may cause more serious side effects such as pancreatitis, thyroid cancer, and allergic reactions.
Comparison with Other GLP-1 Analogues
Mounjaro belongs to a class of drugs that mimic a gut hormone (GLP-1), which stimulates insulin secretion and provides a feeling of satiety. Other GLP-1 analogues, such as Wegovy (semaglutide) and Saxenda (liraglutide), are also prescribed for the treatment of obesity. However, in the absence of robust comparative data, Mounjaro cannot be prioritized over these molecules [[1]].
Reimbursement Conditions
The HAS has recommended reimbursement of Mounjaro for the treatment of obesity, but only in adults with an initial body mass index (BMI) greater than or equal to 35 kg/m², who have failed well-conducted nutritional management (less than 5% weight loss at six months). The commission also considers it necessary to assess the effectiveness of the treatment after six months, and to consider possible discontinuation, particularly in the event of weight loss of less than 5%.
Conclusion
Mounjaro is a promising new-generation drug for the treatment of obesity and type 2 diabetes. While it’s generally safe and effective, it’s essential to follow the recommended guidelines and conditions for reimbursement. As with any medication, it’s crucial to consult with a healthcare professional before starting treatment with Mounjaro. With its potential for greater weight loss and improved management of type 2 diabetes, Mounjaro is an exciting development in the medical community.
